EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Reprint Email

Valeant Pharmaceuticals International Inc (VRX): Today's Featured Health Care Laggard

By TheStreet Wire 08/16/12 - 05:01 PM EDT

Find out if (VRX) is in Cramer's Portfolio.

Valeant Pharmaceuticals International (VRX) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day up 0.6%. By the end of trading, Valeant Pharmaceuticals International fell 66 cents (-1.3%) to $50.61 on light volume. Throughout the day, 1.4 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.9 million shares. The stock ranged in price between $50.06-$51.10 after having opened the day at $50.71 as compared to the previous trading day's close of $51.27. Other companies within the Health Care sector that declined today were: Idenix Pharmaceuticals (IDIX), down 29.7%, Tengion (TNGN), down 15.8%, Palatin Technologies (PTN), down 13.1%, and Kips Bay Medical (KIPS), down 10.4%.

ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $15.18 billion and is part of the drugs industry. The company has a P/E ratio of 267.2, above the average drugs industry P/E ratio of 262.9 and above the S&P 500 P/E ratio of 17.7. Shares are up 9.8% year to date as of the close of trading on Wednesday. Currently there are 14 analysts that rate Valeant Pharmaceuticals International a buy, one analyst rates it a sell, and two rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and unimpressive growth in net income.

You can view the full Valeant Pharmaceuticals International Ratings Report.

On the positive front, Geron Corporation (GERN), up 18.7%, BioMimetic Therapeutics (BMTI), up 15.2%, Columbia Laboratories (CBRX), up 11.9%, and Galena Biopharma (GALE), up 11%, were all gainers within the health care sector with Cigna (CI) being today's featured health care sector leader.

Use our health care section to find sector-relevant news.
Or find some new ideas from our top rated stocks lists.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR (XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care (RXD).

Find other investment ideas from our top rated ETFs lists.

For more information on Valeant Pharmaceuticals International Inc click any of the following:

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:

$2.5+ million portfolio
Large-cap and dividend focus
Intraday trade alerts from Cramer
Weekly roundups

TheStreet Quant Ratings

TRY IT FREE

New! $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:

Buy, hold, or sell recommendations for over 4,300 stocks
Unlimited research reports on your favorite stocks
A custom stock screener
Upgrade/downgrade alerts

Stocks Under $10

TRY IT FREE

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:

Model portfolio
Stocks trading below $10
Intraday trade alerts
Weekly roundups

Dividend Stock Advisor

TRY IT FREE

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:

Diversified model portfolio of dividend stocks
Alerts when market news affect the portfolio
Bi-weekly updates with exact steps to take - BUY, HOLD, SELL

Real Money Pro

TRY IT FREE

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:

Real Money + Doug Kass + 15 more Wall Street Pros
Intraday commentary & news
Ultra-actionable trading ideas

Options Profits

TRY IT FREE

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.